Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Transcode Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Transcode Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Fitzgerald Thomas A | Chief Financial Officer | 56,318 | Sep 11, 2026 | 1 |
| CK Life Sciences Intl (Holdings) Inc | 10% Owner | 14,134,481 | Aug 5, 2026 | 1 |
| Defj, LLC | 10% Owner | 14,134,481 | Aug 5, 2026 | 1 |
| Marquet Magda | Director | – | Jun 18, 2024 | 0 |
| Calais Philippe | Director | – | Jun 18, 2024 | 0 |
| Manting Erik | Director | – | Jun 18, 2024 | 0 |
| Dudley Robert Michael | Chief Executive Officer | 180,262 | Oct 2, 2023 | 0 |
| Medarova Zdravka | Chief Technology Officer | – | Dec 14, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2023 (view filing) | Sep 28 | 4 days | Fitzgerald Thomas AChief Financial Officer | PPurchase | +49.4K | $0.51 | +$25.2K | +708.2%56.3K after | |
| Oct 2, 2023 (view filing) | Sep 28 | 4 days | Dudley Robert MichaelChief Executive Officer | PPurchase | +98.0K | $0.51 | +$50.0K | +119.1%180.3K after | |
| Jun 22, 2023 (view filing) | Jun 20-21 | 2 days | Dudley Robert MichaelChief Executive Officer | PPurchase | +18.6K | $2.61 | +$48.6K | +29.2%82.3K after | 2 lots |
| Jun 14, 2023 (view filing) | Jun 9 | 5 days | Dudley Robert MichaelChief Executive Officer | PPurchase | +19.0K | $2.76 | +$52.4K | +45.1%61.2K after | Amended |
| Sep 16, 2022 (view filing) | Sep 14 | 2 days | Dudley Robert MichaelChief Executive Officer | PPurchase | +20.0K | $1.15 | +$23.0K | +2.3%893.1K after | |
| Jun 17, 2022 (view filing) | Jun 16 | 1 day | Fitzgerald Thomas AChief Financial Officer | PPurchase | +12.0K | $1.27 | +$15.2K | +9.4%139.4K after | |
| Jun 1, 2022 (view filing) | May 27-31 | 5 days | Dudley Robert MichaelChief Executive Officer | PPurchase | +30.0K | $1.84 | +$55.3K | +3.6%873.1K after | 2 lots |